Please login to the form below

Not currently logged in
Email:
Password:

Lilly names Plowman as oncology research chief

Eli Lilly has selected Greg Plowman, formerly senior director at Roche Group's Genentech, to lead its oncology research efforts

Eli Lilly and Company has appointed Greg Plowman as the vice president, oncology research and senior vice president of ImClone Systems research.

Plowman will oversee the oncology research efforts of Lilly and its subsidiary, ImClone. Plowman will be based at ImClone's Alexandria Center for Life Science in New York City, US.

Plowman served as a senior director in research for six years at Genentech, a member of the Roche Group. He has 25 years of experience in cancer research including leadership roles at Oncogene, Sugen, Exelixis and Genentech, which became part of Bristol-Myers Squibb, Pharmacia and Roche.

Lilly acquired ImClone in 2008, broadening its portfolio and strengthening its oncology pipeline and biotech capabilities. The company has one of the largest clinical-stage pipelines of potential cancer medicines in the industry with more than 30 molecules.

 

10th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics